Abstracts tagged "DMARDs"

Abstract Number: 1278 • 2012 ACR/ARHP Annual Meeting
Tuberculosis and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
Kevin L. Winthrop¹, S.-H. Park², A. Gul³, M. Cardiel⁴, JJ Gomez-Reino⁵, D. Ponce de Leon⁶, R. Riese⁷, R. Chew⁷, T. Kawabata⁷, E. Mortensen⁶ and H. Valdez⁸, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²The Catholic University of Korea, Seoul, South Korea, ³Istanbul University, Istanbul, Turkey, ⁴Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, ⁵Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁶Pfizer Inc., Collegeville, PA, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., New York, NY
Background/Purpose: Biologic therapies that block tumor necrosis factor-alpha (TNF) increase the risk of tuberculosis (TB), and screening for latent tuberculosis infection (LTBI) before their initiation…
Abstract Number: 378 • 2012 ACR/ARHP Annual Meeting
Use of Anti-Tumor Necrosis Factor Monotherapy and Adherence with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs in Combination with Anti-Tumor Necrosis Factor Therapy Among Rheumatoid Arthritis Patients in a Real-World Setting
Nicole M. Engel-Nitz¹, Sarika Ogale² and Mahesh Kulakodlu¹, ¹Observational Research, OptumInsight, Eden Prairie, MN, ²Genentech, South San Francisco, CA
Background/Purpose: Studies have shown better response for anti-TNFs (aTNF) when they are used in combination with non-biologic DMARDs (nbDMARD), than when used as monotherapies.1 Therefore,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].